Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mylan Gets EU Rights for Fujifilm Kyowa Kirin Biologics’ Humira Biosimilar
Fujifilm Kyowa Kirin Biologics, a joint venture between Fujifilm and Kyowa Hakko Kirin, said on April 11 that it has granted Mylan exclusive commercialization rights in Europe to FKB327, a biosimilar version of Humira (adalimumab) now pending approval in the…
To read the full story
Related Article
- Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
- Fujifilm Kyowa Kirin, Mylan Bag EU Approval of Humira Biosimilar
September 25, 2018
- Humira Biosimilar Grabs European Panel Backing: Fujifilm Kyowa Kirin/Mylan
July 31, 2018
- EMA Accepts Application for Fujifilm Kyowa Kirin’s Humira Biosimilar
May 23, 2017
BUSINESS
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
- Astellas, MSD File Padcev-Keytruda for Cisplatin-Eligible MIBC in Japan
May 15, 2026
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Takeda’s FY2025 Sales Fall 1.7% on Vyvanse Generic Erosion
May 14, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…